Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N02RS1
- Development stage
- Unknown
- Lead developer
- PharmaKing
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
N02RS1 is a botanical drug candidate developed by PharmaKing for the treatment of acute bronchitis and acute exacerbations of chronic bronchitis. It is a phytoformula consisting of a 1:1 mixture of the ethyl acetate fraction from the root barks of *Broussonetia papyrifera* (paper mulberry) and a 70% aqueous ethanol extract from the whole plant of *Lonicera japonica* (Japanese honeysuckle). The drug exerts its therapeutic effects through a dual mechanism of action involving the inhibition of 5-lipoxygenase (5-LOX) and the down-regulation of proinflammatory cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-1 (IL-1). It has been evaluated in Phase 2 clinical trials in South Korea to assess its efficacy and safety compared to placebo.
- Other names
- Broussonetia and Lonicera extractBroussonetia papyrifera + Lonicera japonicaCombination of Broussonetia spp and Lonicera spp
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL1A (Interleukin 1 alpha)ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on N02RS1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N02RS1.